编造虚假内容，上市首年虚增收入3000万，ST诺泰及实控人等被罚7620万元

Core Viewpoint - ST诺泰 has faced administrative penalties from the China Securities Regulatory Commission (CSRC) and disciplinary actions from the Shanghai Stock Exchange due to significant violations, including fabricating major false content in public offering documents and inflating financial figures in its 2021 annual report [1][3]. Group 1: Regulatory Actions - ST诺泰 received a total fine of 76.2 million yuan from the CSRC, with the company and its actual controller Zhao Dezhong among six individuals penalized [1]. - The CSRC found that ST诺泰's 2021 annual report falsely recorded an increase in operating income of 30 million yuan and inflated total profit by 25.95 million yuan, accounting for 20.64% of the reported profit for that period [3]. - The Shanghai Stock Exchange issued a disciplinary decision against ST诺泰 and the responsible individuals, publicly reprimanding them and imposing restrictions on Zhao Dezhong's ability to serve as a director or submit listing applications for five years [7]. Group 2: Company Background and Financial Performance - ST诺泰, established in 2009 and listed on the Sci-Tech Innovation Board in 2021, focuses on the research and development of peptide drugs and small molecule drugs [5]. - For the first three quarters of 2025, ST诺泰 reported total operating income of 1.527 billion yuan, a year-on-year increase of 21.95%, and a net profit attributable to shareholders of 445 million yuan, up 26.92% [9]. - The company has been involved in the development of new drugs, including an oral formulation of Semaglutide, which has received clinical trial approval from the National Medical Products Administration [11].